Clinical Trials
34 trialsNCT06311214 2026-05-27
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07080333 2026-05-26
MICROBLADDERK
Centre Hospitalier Universitaire de Nice
Phase NA Recruiting
NCT05554380 2026-05-22
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Suspended
NCT04585958 2026-05-20
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT03030378 2026-05-19
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05372614 2026-05-18
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05554341 2026-05-14
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03907475 2026-05-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04317105 2026-05-13
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05327010 2026-05-13
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05638295 2026-05-13
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05687110 2026-05-13
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05687136 2026-05-13
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05691517 2026-05-13
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06223542 2026-05-13
Studying TAK-243 in Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06606990 2026-05-13
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT02079740 2026-04-29
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03842228 2026-04-29
COD
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05763355 2026-04-23
BIOPROSTABORD
Elsan
Phase NA Completed
NCT02342158 2026-04-21
PERMED01
Institut Paoli-Calmettes
Phase NA Completed
NCT05088395 2026-04-14
ALCINA4
Institut Curie
Phase NA Recruiting
NCT02517281 2026-03-20
SKINTARGET
Gustave Roussy, Cancer Campus, Grand Paris
Phase NA Completed
NCT04294628 2026-02-27
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06320405 2025-12-29
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
OHSU Knight Cancer Institute
Phase 1/2 Recruiting
NCT06043713 2025-12-19
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT06782451 2025-09-29
DST
Centre Antoine Lacassagne
Phase NA Recruiting
NCT06628570 2025-09-08
Screening Strategies Among High-risk Populations for Anal Cancer
Emory University
Phase NA Recruiting
NCT03868579 2025-03-05
Rapid On Site Evaluation of Pleural Touch Preparations in Diagnosing Malignant Pleural Effusion in Patients Undergoing Pleuroscopy
M.D. Anderson Cancer Center
Phase NA Completed
NCT05653661 2025-01-07
Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
Mayo Clinic
Phase 1 Withdrawn
NCT00250055 2024-03-12
Non-Invasive, Real-Time Technology for Diagnosis of Cervical Tissue
University of New Mexico
Phase NA Terminated
NCT03333655 2022-08-12
Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy
Hoffmann-La Roche
Phase 4 Completed
NCT04142489 2022-05-06
In Vivo Damage Induced bu UV in the Epidermis of the Scalp
Centre Hospitalier Universitaire de Nice
Phase NA Completed
NCT01856296 2019-06-18
WINTHER
Gustave Roussy, Cancer Campus, Grand Paris
Phase NA Completed
NCT00865813 2009-03-19
Biopsy Incisional With Trepan in Periocular Lesions
University of Sao Paulo
Phase NA Unknown